News | Myriad Genetics

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

Sep 28, 2023 | Products

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Sep 19, 2023 | Products

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

Sep 19, 2023 | Corporate

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Sep 18, 2023 | Products

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

Sep 06, 2023 | Corporate

New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

Sep 06, 2023 | Products

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

Sep 05, 2023 | Corporate | Financial

Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk

Aug 22, 2023 | Products

Myriad Genetics to Host Investor Day on September 19, 2023

Aug 17, 2023 | Corporate

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

Aug 15, 2023 | Products

Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

Aug 08, 2023 | Products

Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Aug 07, 2023 | Products

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

Aug 03, 2023 | Financial | Corporate

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

Jul 27, 2023 | Financial

Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

Jul 24, 2023 | Products

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

Jul 06, 2023 | Financial

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

Jun 12, 2023 | Products

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

Jun 07, 2023 | Corporate | Financial

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

Jun 01, 2023 | Products | Corporate

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

May 31, 2023 | Corporate

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

May 24, 2023 | Products

Myriad Genetics Earns 2023 Great Place to Work Certification™

May 08, 2023 | Corporate

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

May 03, 2023 | Corporate | Financial

Myriad Genetics to Participate in BofA Securities Healthcare Conference

May 02, 2023 | Corporate

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

Apr 26, 2023 | Financial | Corporate

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

Apr 19, 2023 | Products

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

Apr 18, 2023 | Products

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

Apr 12, 2023 | Products | Corporate

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Mar 02, 2023 | Products | Corporate

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

Mar 01, 2023 | Products

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

Feb 28, 2023 | Financial | Corporate

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

Feb 22, 2023 | Financial | Corporate

Myriad Genetics to Participate in Upcoming Healthcare Conferences

Feb 09, 2023 | Financial | Corporate

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

Feb 07, 2023 | Products

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

News Releases

Select year

Categories

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk

Myriad Genetics to Host Investor Day on September 19, 2023

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

Myriad Genetics Earns 2023 Great Place to Work Certification™

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

Myriad Genetics to Participate in BofA Securities Healthcare Conference

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

Myriad Genetics to Participate in Upcoming Healthcare Conferences

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference